Based on encouraging results from the CheckMate 040 and KEYNOTE-224 clinical trials, the United States Federal Drug Administration (FDA) has granted accelerated approval for the PD-1 inhibitors nivolumab and pembrolizumab as second-line treatments for advanced HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.